Perspectives in membranous nephropathy

Nicola M Tomas; Tobias B Huber; Elion Hoxha

doi:10.1007/s00441-021-03429-4

Perspectives in membranous nephropathy

Standard

Perspectives in membranous nephropathy. / Tomas, Nicola M ; Huber, Tobias B ; Hoxha, Elion.

in: CELL TISSUE RES, Jahrgang 385, Nr. 2, 08.2021, S. 405-422.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Tomas, NM , Huber, TB & Hoxha, E 2021, 'Perspectives in membranous nephropathy', CELL TISSUE RES, Jg. 385, Nr. 2, S. 405-422. https://doi.org/10.1007/s00441-021-03429-4

APA

Tomas, N. M., Huber, T. B., & Hoxha, E. (2021). Perspectives in membranous nephropathy. CELL TISSUE RES, 385(2), 405-422. https://doi.org/10.1007/s00441-021-03429-4

Vancouver

Tomas NM , Huber TB , Hoxha E. Perspectives in membranous nephropathy. CELL TISSUE RES. 2021 Aug;385(2):405-422. https://doi.org/10.1007/s00441-021-03429-4

Bibtex

@article{aa971aba8cc54ae9a911dd3143fd0266,

title = "Perspectives in membranous nephropathy",

abstract = "The identification of the phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) as podocyte antigens in adult patients with membranous nephropathy (MN) has strongly impacted both experimental and clinical research on this disease. Evidence has been furnished that podocyte-directed autoantibodies can cause MN, and novel PLA2R- and THSD7A-specific animal models have been developed. Today, measurement of serum autoantibody levels and staining of kidney biopsies for the target antigens guides MN diagnosis and treatment worldwide. Additionally, anti-PLA2R antibodies have been proven to be valuable prognostic biomarkers in MN. Despite these impressive advances, a variety of questions regarding the disease pathomechanisms, clinical use of antibody measurement, and future treatments remain unanswered. In this review, we will outline recent advances made in the field of MN and discuss open questions and perspectives with a focus on novel antigen identification, mechanisms of podocyte injury, clinical use of antibody measurement to guide diagnosis and treatment, and the potential of innovative, pathogenesis-based treatment strategies.",

keywords = "Animals, Glomerulonephritis, Membranous/immunology, Humans",

author = "Tomas, {Nicola M} and Huber, {Tobias B} and Elion Hoxha",

note = "{\textcopyright} 2021. The Author(s).",

year = "2021",

month = aug,

doi = "10.1007/s00441-021-03429-4",

language = "English",

volume = "385",

pages = "405--422",

journal = "CELL TISSUE RES",

issn = "0302-766X",

publisher = "Springer",

number = "2",

}

RIS

TY - JOUR

T1 - Perspectives in membranous nephropathy

AU - Tomas, Nicola M

AU - Huber, Tobias B

AU - Hoxha, Elion

PY - 2021/8

Y1 - 2021/8

N2 - The identification of the phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) as podocyte antigens in adult patients with membranous nephropathy (MN) has strongly impacted both experimental and clinical research on this disease. Evidence has been furnished that podocyte-directed autoantibodies can cause MN, and novel PLA2R- and THSD7A-specific animal models have been developed. Today, measurement of serum autoantibody levels and staining of kidney biopsies for the target antigens guides MN diagnosis and treatment worldwide. Additionally, anti-PLA2R antibodies have been proven to be valuable prognostic biomarkers in MN. Despite these impressive advances, a variety of questions regarding the disease pathomechanisms, clinical use of antibody measurement, and future treatments remain unanswered. In this review, we will outline recent advances made in the field of MN and discuss open questions and perspectives with a focus on novel antigen identification, mechanisms of podocyte injury, clinical use of antibody measurement to guide diagnosis and treatment, and the potential of innovative, pathogenesis-based treatment strategies.

AB - The identification of the phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) as podocyte antigens in adult patients with membranous nephropathy (MN) has strongly impacted both experimental and clinical research on this disease. Evidence has been furnished that podocyte-directed autoantibodies can cause MN, and novel PLA2R- and THSD7A-specific animal models have been developed. Today, measurement of serum autoantibody levels and staining of kidney biopsies for the target antigens guides MN diagnosis and treatment worldwide. Additionally, anti-PLA2R antibodies have been proven to be valuable prognostic biomarkers in MN. Despite these impressive advances, a variety of questions regarding the disease pathomechanisms, clinical use of antibody measurement, and future treatments remain unanswered. In this review, we will outline recent advances made in the field of MN and discuss open questions and perspectives with a focus on novel antigen identification, mechanisms of podocyte injury, clinical use of antibody measurement to guide diagnosis and treatment, and the potential of innovative, pathogenesis-based treatment strategies.

KW - Animals

KW - Glomerulonephritis, Membranous/immunology

KW - Humans

U2 - 10.1007/s00441-021-03429-4

DO - 10.1007/s00441-021-03429-4

M3 - SCORING: Review article

C2 - 33825066

VL - 385

SP - 405

EP - 422

JO - CELL TISSUE RES

JF - CELL TISSUE RES

SN - 0302-766X

IS - 2

ER -